Trial Profile
A Single Center, Single-arm, Phase II Study of Anlotinib in Subjects With Advanced Malignancy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Advanced breast cancer; Gastric cancer; Gastrointestinal stromal tumours; Intestinal cancer; Malignant melanoma; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Jan 2020 New trial record